500 related articles for article (PubMed ID: 36242682)
41. Burden and genotype distribution of high-risk Human Papillomavirus infection and cervical cytology abnormalities at selected obstetrics and gynecology clinics of Addis Ababa, Ethiopia.
Ali KE; Mohammed IA; Difabachew MN; Demeke DS; Haile T; Ten Hove RJ; Kumssa TH; Woldu ZL; Haile EL; Tullu KD
BMC Cancer; 2019 Aug; 19(1):768. PubMed ID: 31382907
[TBL] [Abstract][Full Text] [Related]
42. Impact of HPV molecular testing with partial genotyping as a feasibility study in cervical cancer community screening program in South India.
Ramshankar V; Ravindran S; Arun K; Albert K; Sri SL; Ramasubramanian L; Satyaseelan B
J Med Virol; 2023 Apr; 95(4):e28715. PubMed ID: 37185837
[TBL] [Abstract][Full Text] [Related]
43. Knowledge regarding human papillomavirus and cervical cancer prevention among medical students from Chulalongkorn University in Thailand.
Sukrong M; Prapaisilp P; Juntamongkol T; Siranart N; Phoolcharoen N; Assavapokee N; Sirisabya N; Santibenchakul S
BMC Womens Health; 2024 Feb; 24(1):129. PubMed ID: 38373946
[TBL] [Abstract][Full Text] [Related]
44. Cervical cancer: Part I human papilloma virus vaccination in Taiwan.
Yang ST; Wang PH; Liu HH; Chang WH; Chou FW; Lee WL
Taiwan J Obstet Gynecol; 2024 May; 63(3):320-328. PubMed ID: 38802194
[TBL] [Abstract][Full Text] [Related]
45. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
46. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control.
Ndizeye Z; Vanden Broeck D; Lebelo RL; Bogers J; Benoy I; Van Geertruyden JP
PLoS One; 2019; 14(6):e0209303. PubMed ID: 31237894
[TBL] [Abstract][Full Text] [Related]
48. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
49. HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women.
Hernández-Silva CD; Ramírez de Arellano A; Pereira-Suárez AL; Ramírez-López IG
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543693
[TBL] [Abstract][Full Text] [Related]
50. [What should be known for the introduction of an HPV vaccine?].
Muñoz N; Jacquard AC
Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
[TBL] [Abstract][Full Text] [Related]
51. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
52. Knowledge of Cervical Cancer Screening and Prevention by Human Papillomavirus Deoxyribonucleic Acid and Human Papillomavirus Vaccination among Women Attending a Tertiary Care Centre.
Amatya Vaidya S; Roka Magar L; Magar SB
JNMA J Nepal Med Assoc; 2023 Aug; 61(264):658-661. PubMed ID: 38289809
[TBL] [Abstract][Full Text] [Related]
53. MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China.
Deng S; Welby S; Liu Z; Yang Y; Meng R; Sun Y; Yang J; Liu G; He Y; Jiang N; Wu Z; Liu K; Rosillon D; Cohet C; Borys D; Zhan S
Hum Vaccin Immunother; 2023 Aug; 19(2):2257989. PubMed ID: 37813849
[TBL] [Abstract][Full Text] [Related]
54. Knowledge, attitudes, and practices toward cervical cancer prevention among women in Kampong Speu Province, Cambodia.
Touch S; Oh JK
BMC Cancer; 2018 Mar; 18(1):294. PubMed ID: 29544466
[TBL] [Abstract][Full Text] [Related]
55. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
56. HPV genotype prevalence in Indian women with cervical disease and estimation of the potential impact of HPV vaccines on prevention of cervical cancer.
Nagaraja M; Narendra H; Venkataramana B; Kalawat U
Indian J Med Microbiol; 2023; 43():73-78. PubMed ID: 36241529
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus vaccination and cervical cancer risk.
Rahangdale L; Mungo C; O'Connor S; Chibwesha CJ; Brewer NT
BMJ; 2022 Dec; 379():e070115. PubMed ID: 36521855
[TBL] [Abstract][Full Text] [Related]
58. Variation in genital human papillomavirus infection prevalence and vaccination coverage among men and women in the USA.
Han JJ; Tarney CM; Song J
Future Oncol; 2017 Jun; 13(13):1129-1132. PubMed ID: 28589730
[TBL] [Abstract][Full Text] [Related]
59. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
60. Changes in genital Human Papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program.
Khoo SP; Muhammad Ridzuan Tan NA; Rajasuriar R; Nasir NH; Gravitt P; Ng CW; Woo YL
PLoS One; 2022; 17(12):e0278477. PubMed ID: 36538522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
